$151 Million is the total value of Aisling Capital Management LP's 16 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 5.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BBIO | BridgeBio Pharma Inc. (BBIO) | $46,239,113 | -23.3% | 6,068,125 | 0.0% | 30.53% | -23.8% | |
| VRNA | Verona Pharma plc (VRNA)sponsored ads | $34,817,833 | +155.7% | 1,332,485 | 0.0% | 22.99% | +154.2% | |
| SNDX | Syndax Pharmaceuticals, Inc. (SNDX) | $26,086,250 | +5.9% | 1,025,000 | 0.0% | 17.22% | +5.3% | |
| GLUE | Monte Rosa Therapeutics Inc. (GLUE) | $11,204,439 | -6.9% | 1,472,331 | 0.0% | 7.40% | -7.4% | |
| ACRS | Sell | Aclaris Theraputics Inc. (ACRS) | $6,842,666 | -31.5% | 434,455 | -31.5% | 4.52% | -31.9% |
| BMEA | Biomea Fusion Inc. (BMEA) | $6,733,522 | -13.8% | 798,757 | 0.0% | 4.44% | -14.3% | |
| PSTX | Poseida Therapeutics Inc. (PSTX) | $5,529,315 | +50.1% | 1,043,267 | 0.0% | 3.65% | +49.2% | |
| NUVB | Nuvation Bio Inc. (NUVB) | $4,878,737 | -14.3% | 2,541,009 | 0.0% | 3.22% | -14.8% | |
| ELEV | Elevation Oncology Inc. (ELEV) | $2,693,165 | -15.9% | 2,834,910 | 0.0% | 1.78% | -16.4% | |
| RPHM | Reneo Pharmaceuticals Inc. (RPHM) | $2,064,555 | -30.4% | 886,075 | 0.0% | 1.36% | -30.8% | |
| SPRB | Spruce Biosciences, Inc. (SPRB) | $1,322,446 | -19.9% | 1,205,511 | 0.0% | 0.87% | -20.4% | |
| MRKR | Marker Therapeutics, Inc. (MRKR) | $848,571 | -27.0% | 3,142,857 | 0.0% | 0.56% | -27.5% | |
| AGLE | Aeglea Biotherapeutics Inc. (AGLE) | $761,018 | -14.5% | 1,691,151 | 0.0% | 0.50% | -15.1% | |
| AVRO | AVROBIO, Inc. (AVRO) | $716,943 | +11.0% | 1,009,779 | 0.0% | 0.47% | +10.3% | |
| VIRX | Viracta Therapeutics Inc. (VIRX) | $421,314 | -65.8% | 288,571 | 0.0% | 0.28% | -66.0% | |
| BCEL | Atreca Inc. (BCEL) | $310,510 | -49.0% | 387,653 | 0.0% | 0.20% | -49.3% | |
| TALS | Exit | Talaris Therapeutics Inc. (TALS) | $0 | – | -175,000 | -100.0% | -0.30% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Verona Pharma plc (VRNA) | 20 | Q3 2023 | 23.0% |
| AVROBIO, Inc. (AVRO) | 20 | Q3 2023 | 13.6% |
| Aclaris Theraputics Inc. (ACRS) | 20 | Q3 2023 | 6.6% |
| Aeglea Biotherapeutics Inc. (AGLE) | 19 | Q2 2023 | 7.5% |
| BridgeBio Pharma Inc. (BBIO) | 18 | Q3 2023 | 67.3% |
| Marker Therapeutics, Inc. (MRKR) | 18 | Q1 2023 | 11.7% |
| Atreca Inc. (BCEL) | 18 | Q3 2023 | 3.1% |
| Syndax Pharmaceuticals, Inc. (SNDX) | 15 | Q3 2023 | 17.2% |
| Zosano Pharma Corporation (ZSAN) | 15 | Q2 2022 | 5.8% |
| ObsEva SA (OBSV) | 14 | Q1 2022 | 18.5% |
View Aisling Capital Management LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-03 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-18 |
| 13F-HR | 2021-11-12 |
View Aisling Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.